Drugs / Dubermatinib
Dubermatinib
also known as
TP-0903 · Dubermatinib ditartrate · DUBERMATINIB TARTRATE · HCl-2084 · TP-0903 ditartrate · TP-0903 tartrate
Small molecule targets AXL via inhibition
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04518345 | Nov 2020 → Oct 2021 | therapy related acute myeloid leukemia and myelodysplastic syndrome | Uma Borate | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02729298 | Dec 2016 → Jun 2022 | colorectal carcinoma, non-small cell lung carcinoma, ovarian carcinoma | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03572634 | Jun 2019 → Jan 2020 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Sumitomo Pharma America, Inc. | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03013998 | Nov 2016 → Dec 2032 expected | acute myeloid leukemia | Beat AML, LLC | Recruiting | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dubermatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04518345 ↗ |
| Known as | Dubermatinib ditartrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2022968 ↗ |
| Known as | DUBERMATINIB TARTRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2022968 ↗ |
| Known as | HCl-2084 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2022968 ↗ |
| Known as | TP-0903 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03013998 ↗ |
| Known as | TP-0903 ditartrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2022968 ↗ |
| Known as | TP-0903 tartrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2022968 ↗ |
| Action | Inhibit | “Novel Inhibitor of AXL Kinase” NCT02729298 ↗ |
| Modality | Small molecule | — CHEMBL2022968 ↗ |
| Route | Oral | “administered orally” NCT02729298 ↗ |
| Target | AXL | “targets AXL kinase” NCT02729298 ↗ |